News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
First and only PARP inhibitor to improve invasive disease-free survival in patients
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Alopecia areata usually presents as a few small bald patches in the head
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Subscribe To Our Newsletter & Stay Updated
